Sundar Jagannath, MBBS, discusses takeaways from the FDA’s ODAC consensus on safety considerations with cilta-cel in relapsed/refractory multiple myeloma.
Diagnosing early-stage lung cancer with low-dose computed tomography screening drastically improves the survival rate of cancer patients over a 20-year period, according to a large-scale international study being presented by Mount Sinai researchers at the annual meeting of the Radiological Society of North America.
Joshua Richter, MD, discusses how bispecific antibodies fit into the current treatment armamentarium for patients with multiple myeloma, highlighting his presentation from the 41st Annual CFS®.
The Mount Sinai Medical Legal Partnership, which provides legal aid to Mount Sinai Health System patients in need, has launched a clinic to help breast cancer patients navigate legal issues that arise due to their diagnoses.